PART II
Item5.
Market for Registrant’s Common Equity, Related StockholderMatters and Issuer Purchases of
Equity Securities
Our common stock is traded publicly through The Nasdaq Global Select Market under the symbol ‘‘ISIS.’’
The following table presents quarterly information on the price range of our common stock. This information
indicates the high and low sale prices reported by The Nasdaq Global Select Market. These prices do not include
retail markups, markdowns or commissions.
HIGH LOW
2014
First Quarter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$62.66 $38.04
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$45.04 $22.25
Third Quarter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$43.42 $27.37
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$67.12 $35.26
2013
First Quarter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$19.53 $10.36
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$28.66 $15.92
Third Quarter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$39.83 $23.63
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$42.69 $29.41
As of February 23, 2015, there were approximately 642 stockholders of record of our common stock. We
have never paid dividends and do not anticipate paying any dividends in the foreseeable future.
Set forth below is a table and chart comparing the total return on an indexed basis of $100 invested on
December 31, 2009 in our common stock, the NASDAQComposite Index (total return) and the NASDAQ
Biotechnology Index. The total return assumes reinvestment of dividends.
Performance Graph (1)
$0
$100
$200
$300
$400
$500
$600
12/09
12/10
12/11
12/12
12/13
12/14
COMPARISONOF5YEARCUMULATIVETOTALRETURN*
Among IsisPharmaceuticals, Inc., theNASDAQComposite Index,
and theNASDAQBiotechnology Index
IsisPharmaceuticals, Inc.
NASDAQComposite
NASDAQBiotechnology
*$100 investedon 12/31/09 in stock or index, including reinvestment of dividends.
Fiscal year endingDecember 31.
65
